Pazopanib for Non-small Cell Lung Cancer: The First Case Report in Korea.
- Author:
Jaemin JO
1
;
Jung Ho KIM
;
Ji Young KIM
;
Changlim HYUN
;
Jiyoung RHEE
;
Jungmi KWON
;
Sanghoon HAN
;
Wookun KIM
Author Information
- Publication Type:Case Report
- Keywords: Lung neoplasms; Drug therapy; Tyrosine kinase inhibitor; Pazopanib
- MeSH: Aged; Carcinoma, Non-Small-Cell Lung*; Carcinoma, Renal Cell; Carcinoma, Squamous Cell; Disease-Free Survival; Drug Therapy; Humans; Korea*; Lung; Lung Neoplasms; Protein-Tyrosine Kinases
- From:Cancer Research and Treatment 2016;48(1):393-397
- CountryRepublic of Korea
- Language:English
- Abstract: Pazopanib is a potent multitargeted tyrosine kinase inhibitor that has been shown to have good efficacy in patients with renal cell carcinoma. A previous phase II trial demonstrated that short-term pazopanib administration was generally well tolerated and showed antitumor activity in patients with early-stage non-small cell lung cancer. Herein, we report on the case of a 66-year-old man with simultaneous metastatic squamous cell carcinoma of the lung and renal cell carcinoma who was treated with pazopanib. The patient showed an unexpected partial response and experienced a 10-month progression-free survival without significant toxicity. To the best of the authors' knowledge, this is the first report of pazopanib treatment in a non-small cell lung cancer patient in Korea. The results in this patient suggest that pazopanib may be a valid treatment option for advanced non-small cell lung cancer.
